By [Your Name/Journalist Name]
October 25, 2025
The landscape of breast cancer treatment has shifted dramatically over the last decade, moving from a binary of "cured" or "terminal" toward a more nuanced reality of chronic disease management. For Miriam Sabo, this reality began with a diagnosis that bypassed the early stages entirely. At age 42, Sabo was diagnosed with de novo metastatic breast cancer (MBC)—a condition where the cancer has already spread to distant organs at the time of initial discovery.
Now, six and a half years into her journey, Sabo’s story serves as a profound case study in the evolution of MBC care, the psychological resilience required for lifelong treatment, and the critical role of specialized support networks. Her experience highlights a growing demographic of patients who are "living with" rather than "dying from" a disease that was once considered an immediate death sentence.
Main Facts: Redefining the Stage 4 Narrative
Metastatic breast cancer, also known as Stage 4, occurs when cancer cells break away from the original tumor site in the breast and travel through the circulatory or lymphatic system to other parts of the body, such as the bones, lungs, brain, or—in Sabo’s case—the liver.
While many patients progress to Stage 4 years after an initial early-stage diagnosis, Sabo belongs to the "de novo" category. According to clinical data, approximately 6% of new breast cancer diagnoses in the United States are de novo metastatic. For these patients, there is no "before" or "early catch"; the first time they hear the word "cancer," it is accompanied by the knowledge that the disease is non-curative.
Sabo’s perspective challenges the traditional "warrior" rhetoric often associated with breast cancer. "The image of fighter gloves and slogans of ‘we’re gonna beat this’ were not going to be my narrative," Sabo explains. Instead, she adopts the term "non-curative" over "terminal," reflecting a medical shift where Stage 4 is increasingly treated as a chronic condition requiring indefinite, sequential therapies.
Chronology: Six and a Half Years of "Forever"
The timeline of Miriam Sabo’s journey illustrates the endurance required for modern MBC patients.
The Initial Shock (Year 0)
In 2019, at the age of 42, Sabo received the diagnosis that the cancer had already reached her liver. This period was marked by the immediate dismantling of a "remission" goal. Unlike Stage 1 or 2 patients who undergo a set course of chemotherapy, radiation, or surgery with the hope of being declared "cancer-free," Sabo had to reconcile with the reality of being in treatment for the rest of her life.
Seeking Specialized Support (Years 1-2)
Early in her diagnosis, Sabo turned to Sharsheret, a national non-profit organization dedicated to supporting Jewish women and families facing breast and ovarian cancer. Having previously engaged with the organization for BRCA genetic testing (for which she tested negative), she reconnected to navigate the complexities of Stage 4. Through Sharsheret’s "Embrace" program, specifically designed for those living with metastatic disease, Sabo was paired with clinical social workers and peer supporters who understood the unique isolation of a non-curative diagnosis.
Sustaining Life and Milestones (Years 3-6)
Over the next four years, the focus shifted from crisis management to "living life." During this window, Sabo witnessed her four children grow, attended their graduations, and celebrated the weddings of two of them. This period exemplifies the success of modern systemic therapies—such as CDK4/6 inhibitors, targeted HER2 therapies, and advanced endocrine treatments—which aim to stall disease progression while maintaining a high quality of life.
The Present (6.5 Years and Beyond)
Today, Sabo continues to outpace the historical statistics for MBC survival. She has transitioned from a seeker of support to a peer supporter herself, helping other women navigate the "de novo" path. Her mantra—"I’m not milk; there’s no expiration date stamped on me"—reflects the current clinical push to treat the patient, not the statistic.
Supporting Data: The Statistics of Metastatic Breast Cancer
To understand the weight of Sabo’s 6.5-year milestone, one must look at the broader epidemiological data surrounding MBC. Historically, the five-year survival rate for metastatic breast cancer was significantly lower than it is today.
- Survival Trends: According to the National Cancer Institute’s SEER (Surveillance, Epidemiology, and End Results) database, the five-year relative survival rate for metastatic breast cancer has been steadily climbing. In the early 1990s, it hovered around 18-20%. For women diagnosed between 2014 and 2020, that number rose to approximately 31%, with even higher rates for specific subtypes like Hormone Receptor-positive (HR+) cancer.
- The "De Novo" Advantage: Interestingly, some studies suggest that de novo MBC patients may have a slightly better prognosis than those whose cancer recurs after earlier treatment. This is often because de novo tumors have not yet been exposed to—and therefore have not yet developed resistance to—common chemotherapy or hormonal agents.
- Treatment Longevity: The introduction of targeted therapies has revolutionized the timeline. Patients can now stay on a single line of treatment for years before the cancer finds a "workaround," at which point they move to the next "line" of therapy. This "ladder" of treatment options is what allows patients like Sabo to plan for future weddings and graduations.
Official Responses: The Role of Support Systems
Organizations like Sharsheret have recognized that the needs of metastatic patients differ fundamentally from those with early-stage cancer.
The Sharsheret "Embrace" Program
Bonnie Beckoff, the Director of Social Services and the Embrace program, emphasizes that the psychological burden of MBC involves "living in the middle." While early-stage patients focus on "getting over the hump," MBC patients must manage "scanxiety"—the recurring trauma of scans every three months to check for progression—while trying to maintain a sense of normalcy.
The official response from the medical and advocacy community has been to increase funding for MBC-specific research. Currently, it is estimated that only 7-10% of all breast cancer research funding is directed toward metastatic disease, a discrepancy that advocates are working to change. Organizations are now focusing on:
- Palliative Care Integration: Not as end-of-life care, but as "supportive care" that starts at diagnosis to manage side effects and mental health.
- Peer Support Models: Sharsheret’s model of pairing patients with others in the same "stage" helps combat the "pink-washing" of breast cancer, which often focuses on "survivors" and can make metastatic patients feel invisible.
Implications: The Shift from "Terminal" to "Chronic"
Miriam Sabo’s journey has broader implications for how society, the medical establishment, and patients view late-stage cancer.
1. The Language of Oncology
The shift from "terminal" to "non-curative" or "chronic" is not merely semantic; it changes the clinical approach. When a disease is viewed as chronic, the focus shifts to long-term toxicity management. Doctors must consider how a drug will affect a patient’s ability to work, parent, and travel over five or ten years, rather than just six months.
2. Mental Health and Faith
For Sabo, the intersection of faith and medicine has been a cornerstone of her longevity. In the Jewish community, the concept of "Bitchon" (trust in G-d) plays a significant role in how patients process health crises. Sabo’s reliance on her faith that "G-d’s plans are always for good" highlights the necessity of spiritual and psychological support in the oncology suite.
3. Economic and Social Impact
As more patients live longer with MBC, there are growing implications for the workforce and healthcare policy. "Living with cancer" means more people requiring long-term disability accommodations, consistent access to high-cost medications, and ongoing mental health services. The "success" of keeping patients alive longer creates a new set of challenges in ensuring those extra years are lived with dignity and financial stability.
4. The Visibility of the 30%
It is a common statistic in the advocacy world that nearly 30% of women diagnosed with early-stage breast cancer will eventually progress to metastatic disease. Sabo’s visibility as a 6.5-year "thriver" provides a necessary counter-narrative to the fear surrounding Stage 4. Her story suggests that while the "fighter" narrative may not fit, a narrative of "endurance and presence" is entirely possible.
Conclusion: Beyond the Expiration Date
Miriam Sabo’s story is a testament to the fact that a diagnosis of Stage 4 breast cancer is a change in life’s direction, not necessarily its immediate end. By rejecting the "expiration date" and leaning into specialized support systems like Sharsheret, she has carved out a life defined by presence rather than prognosis.
As medical science continues to advance, the hope is that Sabo’s 6.5-year milestone becomes the floor, not the ceiling, for those diagnosed with metastatic disease. For now, she continues to live day-in and day-out, proving that even in the face of a "non-curative" diagnosis, there is a profound amount of life to be lived.
About the Author
